PLM60
As of the edition of 20 October 2026, PLM60 is a drug known only by a code name: stopped in 2025; acts on TOP2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Code name only
- Registered trials
- 2, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of PLM60.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | P11388 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 0 | 2 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cspc | Lead sponsor of trials | 2020 to now |
| Conjupro Biotherapeutics | Lead sponsor of trials | 2021 to now |